tweenvest

Fujian Haixi Pharmaceuticals Co., Ltd. (SEHK: 2637)

Health Care · Pharmaceuticals · CN

HK$156.00

-0.32% today · +18.2% 1Y

Public summary
A free snapshot of Fujian Haixi Pharmaceuticals Co., Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Fujian Haixi Pharmaceuticals Co., Ltd. (SEHK: 2637) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.57B and employs 200 people.

Over the last twelve months the share price has gained 18.2%, trading between 121.60 and 302.40.

Tweenvest scores Fujian Haixi Pharmaceuticals Co., Ltd. across four factors: quality 95/100, value 58/100. Its strongest factor is quality.

2637 price history

Nov 21, 2025 · 126.00Weekly closes 125.30 – 261.00Nov 13, 2026 · 156.00

Key figures

Market cap
$1.57B
Revenue (TTM)
$87.43M
P/E
67.67
EPS
2.58
Dividend yield
—
Beta (5Y)
—
52-week high
HK$302.40
52-week low
HK$121.60
Avg volume (3M)
—
Shares outstanding
78.71M
Employees
200
Next earnings
—

About Fujian Haixi Pharmaceuticals Co., Ltd.

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo, a generic of cinacalcet hydrochloride tablets; and Saixifu, a generic of hydroxychloroquine sulfate tablets. Further, it provides Haibiping, a generic of valsartan and amlodipine tablets; Anyoufan, a generic of escitalopram oxalate tablets; Haikexi, a generic of valsartan tablets; Anfeiping, a generic of diclofenac sodium enteric-coated tablets; and Jishuning, a generic of cetirizine hydrochloride oral solution. Additionally, the company's pipeline includes C019199, a drug candidate targeting the modulation of the immunosuppressive tumor microenvironment for the treatment of advanced osteosarcoma, which has completed phase II clinical trials; HXP056, an oral small-molecule drug designed to treat retinopathy-related diseases, which has completed phase I clinical trial; HXP089, an oral small-molecule drug targeting glioblastoma multiforme; and HXP090, an oral small-molecule drug designed specifically targeting idiopathic pulmonary fibrosis. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms. Fujian Haixi Pharmaceuticals Co., Ltd. was incorporated in 2012 and is based in Fuzhou, China.

ISIN
CNE100007515
Founded
2012
Listed since
Dec 8, 2025
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
Shanghai Shyndec Pharmaceutical Co., Ltd.SHSE: 600420$1.60BCN¥7.97-1.24%
Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287$1.60BCN¥18.79+0.54%
Braveheart Bio, Inc.NasdaqGM: BRVE$1.59B$19.49-0.66%
Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572$1.57BCN¥4.12-0.48%
Vigonvita Life Sciences Co., Ltd.SEHK: 2630$1.55BHK$72.65-3.13%
Marksans Pharma LimitedNSEI: MARKSANS$1.53BRs318.50-0.47%
PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725$1.51BCN¥43.40-5.28%
ANI Pharmaceuticals, Inc.NasdaqGM: ANIP$1.51B$71.47+2.11%

Browse every Pharmaceuticals company →